Effector Therapeutics Total Risk Alpha
| EFTR Stock | | | USD 0.0002 0.00 0.00% |
The Total Risk Alpha calculation for Effector Therapeutics draws on price and volume history. All inputs are based on actual trading observations from supported exchanges. Effector Therapeutics has a market cap of 940, current ratio of 1.79. See
Investing Opportunities for portfolio-level analysis. Monitoring Effector Therapeutics within a portfolio highlights how it interacts with other holdings. This view summarizes available data without implying outcomes. Broader economic conditions can influence Effector Therapeutics's company valuation — related indicators include
signals in population.
For more information on Effector Stock please use our
How to Invest in Effector Therapeutics overview. It covers the key aspects of trading Effector Stock.
Effector Therapeutics has current Total Risk Alpha of 4.42. The total risk alpha measures the performance of an asset by comparing its returns with those of a selected benchmark portfolio.
Total Risk Alpha | = | RFR + (ER[b] - ER[a]) | x | STD[a] / STD[b] |
| = | 4.42 | |
| ER[a] | = | Expected return on investing in Effector Therapeutics |
| ER[b] | = | Expected return on market index or selected benchmark |
| STD[a] | = | Standard Deviation of returns on Effector Therapeutics |
| STD[b] | = | Standard Deviation of selected market or benchmark |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
Total Risk Alpha Peers Comparison
Total Risk Alpha Relative To Other Indicators
Effector Therapeutics is ranked
second for total risk alpha against industry peers. It is currently under evaluation for maximum drawdown against industry peers with Maximum Drawdown measuring nearly
60.34 against Total Risk Alpha. Maximum Drawdown runs about
60.34 times Total Risk Alpha for Effector Therapeutics
The benchmark portfolio represents the market risk matched to the total risk of the stock ETF or fund.
Compare Effector Therapeutics to Peers
Other Technical Indicators